Vinetz says he was originally motivated to look into camostat mesylate after he saw an April 2020 study published in Cell that showed how this medicine could prevent SARS-CoV-2 from entering cells.ĭr. (With the Omicron variant, those symptoms can still occur, but not as often as it has with other variants.) How the 'surprise' finding on loss of taste and smell was discoveredĭr. But for others, the effect lingers in varying degrees. For many, the senses return as the infection fades. This matters because loss of smell, known as anosmia, and loss of taste are common COVID-19 symptoms. “The patients who received the drug didn’t lose any sense of smell or taste. But, to the researchers’ surprise, it brought a different type of benefit. It showed that the medication, called camostat mesylate, did little to lessen viral load. The study, which is available on a preprint site and has not yet been published in a peer-reviewed journal, ran from June 2020 to April 2021. The scientists, led by Joseph Vinetz, MD, an infectious diseases specialist, were interested to find out if an oral medication used to treat pancreatitis could reduce the viral load (the amount of virus in your body) of SARS-CoV-2 and improve symptoms in people newly diagnosed with COVID-19. ![]() Loss of smell and taste-a hallmark symptom of COVID-19-was not on the minds of a group of Yale School of Medicine researchers when they embarked on a study in the spring of 2020.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |